GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alpine Immune Sciences Inc (STU:34LA) » Definitions » Shiller PE Ratio

Alpine Immune Sciences (STU:34LA) Shiller PE Ratio : (As of May. 12, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Alpine Immune Sciences Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Alpine Immune Sciences Shiller PE Ratio Historical Data

The historical data trend for Alpine Immune Sciences's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alpine Immune Sciences Shiller PE Ratio Chart

Alpine Immune Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Alpine Immune Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Alpine Immune Sciences's Shiller PE Ratio

For the Biotechnology subindustry, Alpine Immune Sciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alpine Immune Sciences's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alpine Immune Sciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Alpine Immune Sciences's Shiller PE Ratio falls into.



Alpine Immune Sciences Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Alpine Immune Sciences's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Alpine Immune Sciences's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.138/129.4194*129.4194
=0.138

Current CPI (Dec. 2023) = 129.4194.

Alpine Immune Sciences Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -1.379 99.695 -1.790
201406 -1.352 100.560 -1.740
201409 -0.896 100.428 -1.155
201412 -1.239 99.070 -1.619
201503 -1.189 99.621 -1.545
201506 -5.025 100.684 -6.459
201509 -1.390 100.392 -1.792
201512 -1.542 99.792 -2.000
201603 -1.832 100.470 -2.360
201606 -1.958 101.688 -2.492
201609 -1.711 101.861 -2.174
201612 -1.896 101.863 -2.409
201703 -2.132 102.862 -2.682
201706 -0.854 103.349 -1.069
201709 0.151 104.136 0.188
201712 -0.264 104.011 -0.328
201803 -0.308 105.290 -0.379
201806 -0.488 106.317 -0.594
201809 -0.754 106.507 -0.916
201812 -0.703 105.998 -0.858
201903 -0.620 107.251 -0.748
201906 -0.566 108.070 -0.678
201909 -0.563 108.329 -0.673
201912 -0.297 108.420 -0.355
202003 -0.271 108.902 -0.322
202006 -0.471 108.767 -0.560
202009 -0.238 109.815 -0.280
202012 -0.222 109.897 -0.261
202103 -0.378 111.754 -0.438
202106 -0.382 114.631 -0.431
202109 -0.468 115.734 -0.523
202112 -0.460 117.630 -0.506
202203 -0.227 121.301 -0.242
202206 -0.568 125.017 -0.588
202209 -0.424 125.227 -0.438
202212 -0.387 125.222 -0.400
202303 -0.262 127.348 -0.266
202306 -0.249 128.729 -0.250
202309 -0.225 129.860 -0.224
202312 0.138 129.419 0.138

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Alpine Immune Sciences  (STU:34LA) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Alpine Immune Sciences Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Alpine Immune Sciences's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Alpine Immune Sciences (STU:34LA) Business Description

Traded in Other Exchanges
Address
188 East Blaine Street, Suite 200, Seattle, WA, USA, 98102
Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company dedicated to discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. Its approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its pipeline candidates are; ALPN-303, or povetacicept, is a dual antagonist of the B cell activating factor, or BAFF, and a proliferation-inducing ligand, or APRIL, cytokines, which play key roles in the activation, development, and survival of B cells, and ALPN-101, or acazicolcept, is a dual Inducible T cell Costimulator, or ICOS, and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.

Alpine Immune Sciences (STU:34LA) Headlines

No Headlines